Tubulis closed one of Europe’s largest Series C rounds—raising €308 million (reported variously as ~$356–361 million)—to advance its clinical‑stage antibody‑drug conjugate (ADC) portfolio and expand trials into earlier lines and additional tumor types. The financing will support ongoing development of TUB‑040 and follow‑on ADC candidates and accelerate biomarker and indication expansion plans. Tubulis designs ADC components in‑house to optimize payload delivery and drug‑to‑antibody ratios; the company said the new capital will fund broader testing in ovarian and non‑small cell lung cancers and support manufacturing and regulatory activities ahead of pivotal reads. Investors signaled confidence in ADC innovation and the company’s differentiation strategy. The round marks renewed investor appetite for oncology platforms that promise better therapeutic windows and earlier‑line positioning. Expect Tubulis to present emerging clinical data at upcoming oncology conferences that will be watched for signals on safety, efficacy, and potential registration paths.